In addition, ibrutinib suppresses the secretion of CXCL13, which can attract and protect CLL cells from tumour-associated macrophages or nurse-like cells in the bone marrow of patients with CLL [35]. This evidence concerns the gene CXCL13 and B-cell chronic lymphocytic leukemia.